Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Collegium Pharma Q3 revenue slightly misses estimates

By Reuters News


Overview

  • U.S. biopharma firm's Q3 revenue rose 3% yr/yr, slightly missing analyst expectations

  • Adjusted EPS for Q3 fell yr/yr

  • Company announced $50 mln accelerated share repurchase program


Outlook

  • Company reaffirms 2026 product revenue guidance of $825 mln to $855 mln

  • Company expects 2026 JORNAY PM revenue of $190 mln to $200 mln

  • Company maintains 2026 adjusted EBITDA forecast of $445 mln to $470 mln


Result Drivers

  • ADHD PORTFOLIO GROWTH - Co said strong demand and expanded commercial efforts drove ADHD portfolio revenue, led by JORNAY PM's 24% yr/yr growth

  • AZSTARYS ACQUISITION - First full quarter of AZSTARYS under co ownership contributed $26.5 mln in revenue, reversing prior prescription declines

  • PAIN PORTFOLIO DECLINE - Pain portfolio revenue fell 18% yr/yr, with declines across key products


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Miss*

$216.30 mln

$217.28 mln (7 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Collegium Pharmaceutical, Inc. is $48.50, about 104.9% above its November 4 closing price of $23.67

  • The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 5 three months ago


Reuters Recommended Reads

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 3 - Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.